Demographics of Patients Examined in Each Phase of This Study
| Demographic | Phase 1 (555 MBq) YNHH | Phase 2 (370 MBq) YNHH | Phase 2 (3.7 MBq/kg) CNR/FTGM |
| Sex (F/M) | 25/26 | 25/18 | 14/12 |
| Age (y) | 56.5 ± 18.8 (13–85) | 63.2 ± 14.1 (20–92) | 60.8 ± 13.4 (23–79) |
| Body mass index (kg/m2) | 29.0 ± 8.5 (16.4–62.0) | 27.5 ± 6.6 (16.3–47.8) | 25.7 ± 3.9 (19.5–31.1) |
| Dose | |||
| mCi | 15.1 ± 1.7 (10.7–19.2) | 10.4 ± 0.9 (8.4–12.9) | 8.2 ± 1.3 (5.4–10.6) |
| MBq | 559 ± 62.8 (396–711) | 383 ± 34.9 (311–478) | 303 ± 49.1 (201–392) |
| Dose/kg | |||
| mCi/kg | 0.21 ± 0.07 (0.08–0.39) | 0.14 ± 0.03 (0.09–0.23) | 0.11 ± 0.01 (0.10–0.16) |
| MBq/kg | 7.8 ± 2.4 (3.1–14.4) | 5.2 ± 1.3 (3.3–8.5) | 4.1 ± 0.5 (3.6–5.8) |
| Blood glucose (mg/dL) | 117.5 ± 30.2 (57–226) | 110.7 ± 16.3 (76–153) | 100.7 ± 10.6 (77–136) |
| Uptake time (min) | 67.7 ± 10.3 (54–107) | 66.4 ± 8.0 (50–91) | 63.6 ± 7.7 (56–80) |
Data are average ± SD, followed by range in parentheses.